Company profile: Kither Biotech
1.1 - Company Overview
Company description
- Provider of pharmaceutical drug development targeting chronic inflammatory diseases, with inhaled therapies such as KIT2014, a cAMP-modulating peptide add-on for cystic fibrosis that enhances CFTR function, reduces mucus, and limits airway inflammation, and KITCL27, an inhaled PI3K-inhibitor prodrug for idiopathic pulmonary fibrosis activated in target cells to minimize systemic side effects.
Products and services
- Chronic Inflammation Drug R&D: Small-peptide–oriented research and development program architected to create new pharmaceutical products targeting chronic inflammatory diseases, concentrating Kither’s first-line activities on novel drug candidates
- KITCL27: A cell-activated prodrug, small-molecule PI3K inhibitor for idiopathic pulmonary fibrosis, suitable for inhalation and designed to minimize systemic side effects by activating only inside target cells
- KIT2014: An inhalation-formulated, small-peptide cAMP modulator for cystic fibrosis that augments CFTR protein function, decreases mucus hypersecretion, and curtails airway inflammation as an add-on therapy
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Kither Biotech
CytoDyn
HQ: United States
Website
- Description: Provider of biotechnology therapies developing Leronlimab, a CCR5-targeting humanized monoclonal antibody for HIV to prevent viral entry into T-cells; exploring uses in NASH to address liver health, fibrosis and cirrhosis; oncology to inhibit tumor growth and metastasis; COVID-19 to modulate immune response and potentially reduce inflammation; and pre-clinical glioblastoma studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CytoDyn company profile →
Galapagos
HQ: Belgium
Website
- Description: Provider of small molecule medicines and investigational therapies in immunology and oncology. Develops CAR-T cell therapies via a decentralized manufacturing network and advances GLPG5101 (Phase 1/2 for relapsed/refractory non-Hodgkin lymphoma). Conducts clinical trials to evaluate treatments and seek regulatory approval; Jyseleca (filgotinib) transferred to Alfasigma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Galapagos company profile →
Forward Pharma
HQ: Denmark
Website
- Description: Provider of biotechnology focused on the immunomodulatory compound dimethyl fumarate and derivatives for pharmaceutical drug applications to treat immune disorders such as multiple sclerosis and psoriasis; founded in 2005 and headquartered in Copenhagen, Denmark.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Forward Pharma company profile →
Hycor Biomedical
HQ: United States
Website
- Description: Provider of diagnostic systems and assays for allergy and mast cell activation, including NOVEOS for allergy testing with small sample volumes; NOVEOS assay reagents, consumables, and supplies for specific IgE tests; a Tryptase Assay chemiluminescent microparticle immunoassay for serum tryptase detection; and TASSO+, a capillary blood collection device compatible with NOVEOS.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hycor Biomedical company profile →
Allergy Therapeutics
HQ: United Kingdom
Website
- Description: Provider of European-based speciality pharmaceutical expertise focused on the treatment and prevention of allergy, offering general information for allergy sufferers and healthcare professionals on prevention, diagnosis and treatment, with a special focus on allergy vaccination (also known as specific immunotherapy or desensitisation therapy).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allergy Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Kither Biotech
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Kither Biotech
2.2 - Growth funds investing in similar companies to Kither Biotech
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Kither Biotech
4.2 - Public trading comparable groups for Kither Biotech
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →